ABSTRACT
To evaluate if the organization of glutamatergic fibers systems in the lumbar cord is evident also at other spinal levels, we examined the immunocytochemical distribution of vesicle glutamate transporters 1 and 2 (VGLUT1, VGLUT2) at several different levels of the rat spinal cord. We also examined the expression of VGLUTs in an ascending sensory pathway, the spinocervical tract, and co-localization of VGLUT1 and VGLUT2.
Mainly small VGLUT2-immunoreactive varicosities occurred at relatively high densities in most areas, with the highest density in laminae I-II. VGLUT1 immunolabeling, including small and medium-sized to large varicosities, were more differentiated with the highest density in the deep dorsal horn and in certain nuclei as the internal basilar nucleus, the central cervical nucleus and the column of Clarke. Lamina I and IIo displayed a moderate density of small VGLUT1 varicosities at all spinal levels, although in the spinal enlargements a uniform density of such varicosities were evident throughout laminae I-II in the medial half of the dorsal horn. Corticospinal tract axons displayed VGLUT1, indicating the corticospinal tract as an important source of small VGLUT1 varicosities. VGLUT1 and VGLUT2 were cocontained in small numbers of varicosities in laminae III-IV and IX. Anterogradely labeled spinocervical tract terminals in the lateral cervical nucleus were VGLUT2 immunoreactive.
In conclusion, the principal distribution patterns of VGLUT1 and VGLUT2 are essentially similar throughout the rostrocaudal extension of the spinal cord. The mediolateral differences in VGLUT1 distribution in laminae I-II suggest dual origins VGLUT1 immunoreactive varicosities in this region.
INTRODUCTION
The first observations that the amino acid glutamate has a powerful excitatory action on neurons in the central nervous system, including those in the spinal cord, date back to the 1950's and early 1960's (Hayashi, 1954; Curtis and Watkins, 1960) . However, it took a long time before the concept that glutamate functions as a neurotransmitter was generally accepted, due to the fact that glutamate, in contrast to most other transmitter substances, is present in high concentrations in the brain and is also a crucial component in neuronal metabolism and protein synthesis. Subsequently, glutamate was shown to fulfill the criteria of a neurotransmitter and is now generally accepted as the neurotransmitter in the majority of excitatory synapses in the central nervous system (Fonnum, 1984; Krnjevic, 1986; Watkins, 1986; Broman et al., 2000 Broman et al., , 2004 .
Identification of the neurons and nerve terminals that release glutamate has been hampered by the absence of reliable markers that could be used to label such profiles in tissue sections. Combinations of lesions and biochemical assays have been of value in identifying foremost massive glutamatergic projections such as certain corticofugal tracts (e.g. Fonnum, 1984) . Autoradiographic detection of retrogradely transported D-[ 3 H]aspartate has been a useful marker of also small glutamatergic projections, although this technique does not label all neurons that are presumed to use glutamate as a neurotransmitter (Baughman and Gilbert, 1980, Streit, 1980; Ottersen, 1991) . With the production of antibodies that recognize aldehyde-fixed glutamate in tissue sections, a most valuable tool for studies of glutamate distribution was introduced (Storm-Mathisen et al., 1983) . As glutamate is present in essentially all cellular elements in the central nervous system, it is necessary to use labeling techniques that allow a quantitative analysis and comparison of the labeling of nerve terminals and other tissue profiles. Such a technique is electron microscopic postembedding immunogold labeling, which has been used in a large number of studies to identify putative glutamatergic terminal populations in many parts of the central nervous system including the spinal cord (Broman et al., 2000) . However, due to the ubiquitous presence of glutamate and the relatively small differences in glutamate content between glutamatergic terminals and certain other tissue elements, glutamate immunolabeling is usually of limited value for visualizing glutamatergic fiber systems in tissue sections by light microscopy.
A property that differentiates glutamatergic neurons from non-glutamatergic neurons is their ability to accumulate glutamate in synaptic vesicles prior to exocytotic release (Naito and Ueda, 1985; Maycox et al., 1988; Fykse et al., 1989; Winter and Ueda, 1993) . Thus, the transporters responsible for vesicular glutamate uptake may serve as selective markers for glutamatergic neurons. Recent studies have identified three different vesicular glutamate transporters (Aihara et al., 2000; Bellocchio et al., 2000; Takamori et al., 2000; Fremeau et al., 2001 Fremeau et al., , 2002 Herzog et al., 2001; Gras et al., 2002; Schäfer et al., 2002; Takamori et al., 2002; Varoqui et al., 2002) . Vesicular glutamate transporters 1 and 2 (VGLUT1, VGLUT2)
are expressed throughout the central nervous system in numerous neurons believed on other grounds to use glutamate as neurotransmitter. Generally, VGLUT1 and VGLUT2 show a complementary expression pattern in the brain (Fremeau et al., 2001; Varoqui et al., 2002) . It has been suggested, among others, based on differential expression of these isoforms in mammalian cells, that they define two distinct classes of glutamatergic synapses (Fremeau et al., 2001) . In contrast, the vesicular glutamate transporter 3 (VGLUT3) is expressed in a variety of cells, including GABAergic and monoaminergic neurons as well as astrocytes (Fremeau et al., 2002; Gras et al., 2002; Boulland et al., 2004) . Transient expression of VGLUT3 has also been detected in progenitor cells, and it has been suggested that VGLUT3 may rather have a morphogenetic role during development and a modulatory role on synaptic transmission at non-glutamatergic synapses in the adult (Boulland et al., 2004) .
Glutamatergic synaptic transmission plays a fundamental role in several subregions of the spinal cord (Broman et al., 2004) . However, immunocytochemical localization of VGLUT1
and VGLUT2 in the spinal cord has so far focused on select levels or fiber systems (Kaneko et al., 2002; Varoqui et al., 2002; Li et al., 2003; Todd et al., 2003; Oliveira et al., 2003; Landry et al., 2004; Alvarez et al., 2004; Herzog et al., 2004) . It is therefore uncertain if the conclusions inferred from examination of primarily lumbar levels can be generalized to other rostrocaudal levels of the spinal cord. Further, the distribution patterns of VGLUT1 and VGLUT2 in spinal nuclei present only at non-lumbar levels are unknown. In the present study we examine the detailed distribution and appearance of VGLUT1 and VGLUT2
immunolabeled varicosities at several rostrocaudal levels of the spinal cord and describe certain distribution patterns not previously examined or recognized. Further, we demonstrate that varicosities of the spinocervical tract, an intraspinal sensory pathway, contain VGLUT2.
MATERIALS AND METHODS

Animals
Subject of the study were adult male or female Sprague-Dawley or Wistar rats weighing 250-400 g. The experimental procedures were made according to the European regulations and were approved in advance by the local Animal Care and Use Committees.
Antisera
The antisera used in this study are listed in Table 1 . All three VGLUT1 antisera used produced staining patterns in the spinal cord indistinguishable from each other, as did the two VGLUT2 antisera. Western blot analysis of homogenized rat brains and/or crude synaptic vesicle fractions from rat brains demonstrated a single broad band at about 60 kDa for all three VGLUT1 antisera and a single broad band slightly above 60 kDa for the two VGLUT2
antisera (Bellocchio et al., 1998; Fremeau et al., 2001; Boulland et al., 2004; Chaudhry and Storm-Mathisen, unpublished observations; Antibody data sheets from Synaptic Systems). In COS or PC12 cells transfected with VGLUT1 or VGLUT2 cDNA, immunolabeling with the VGLUT1 and VGLUT2 antisera of Bellocchio et al. (1998) and Fremeau et al. (2001) were only evident when the antisera were applied to cells expressing the corresponding transporter isoform. Furthermore, pre-adsorption of these antisera with the corresponding, but not with the non-corresponding, GST fusion protein used as immunogen, completely abolished immunolabeling of rat brain sections (Bellocchio et al., 1998; Fremeau et al., 2001; Boulland et al., 2004) . Similarly, pre-adsorption of the Synaptic System VGLUT1 and VGLUT2 antibodies with the corresponding, but not with the noncorresponding, immunogen (5 µg/ml diluted antiserum), eliminated all staining in rat spinal cord sections, except for some faint background mainly present in neuronal cell bodies (not shown). This faint background, and an absence of nerve terminal-like labeling, was also evident in sections processed for immunolabeling with normal rabbit serum in place of VGLUT1 or VGLUT2 antiserum. In conclusion, the above control experiments strongly suggest that the VGLUT1 and VGLUT2 immunolabeling reported in this study represents the presence of VGLUT1 and VGLUT2, respectively, in select spinal cord fibers systems.
The mouse monoclonal antibody used for detection of choleragenoid (cholera toxin subunit B, CTb), reacts selectively with the beta chain of the toxin according to ELISA analysis performed by the manufacturer. Sections from the brain and spinal cord of rats not injected with CTb demonstrate no immunolabeling when processed with this antibody, except for some labeling in parts of the area postrema and the medial eminence (i.e., sites with absent blood-brain barrier). This labeling is evident only when the primary antibody is detected with the rabbit anti-mouse antiserum and the mouse monoclonal peroxidase/anti-peroxidase from Dako (i.e., not when detected with the Alexa 488-conjugated antibody) and is also present when sections are processed with other mouse monoclonal antibodies (unpublished observations). Pre-adsorption of the diluted anti-CTb antibody with CTb (5 µg/ml) completely abolished labeling of injected and axonally transported CTb in rats with spinal CTb injections.
In conclusion, the CTb labeling detected with this antibody in the lateral cervical nucleus most likely identifies spinocervical tract terminations originating from the sites of CTb injections in the spinal cord.
VGLUT immunoperoxidase labeling
Spinal cord sections from six Sprague-Dawley rats were used for VGLUT1 and VGLUT2
immunoperoxidase labeling. Deep anesthesia was induced by an overdose of sodium pentobarbital i.p. and the rats were fixed by transcardial perfusion. Following a rinse with 100-200 ml of phosphate buffered saline (PBS, pH 7.4, 300 mOsm) the rats were perfused for 20-25 minutes with 800-1000 ml of 4% (w/v) depolymerized paraformaldehyde in PBS. The spinal cord was then uncovered and in all rats segments C2, C6, T8 or T9 and L4 were harvested, postfixed in the same fixative for two hours and then placed in 30% (w/v) sucrose in PBS overnight at 4°C. In some rats were also parts of adjacent segments harvested and processed. The caudal border of each segment was defined as the level of entrance of its caudal-most dorsal rootlet.
Each spinal cord segment was sectioned transversely on a freezing microtome at 40 µm.
In each group of five serial sections, one was processed for VGLUT1 immunolabeling and another for VGLUT2 immunolabeling. In some of the rats a third section in each group was mounted on slides and stained with thionin. The sections processed for immunolabeling were first blocked for two hours in normal swine serum (DAKO; 1:30) diluted in PBS containing 0.5% (w/v) bovine serum albumin (Sigma) and 0.5% (v/v) Triton X-100 (Sigma) (PBST). The sections were then incubated free-floating in PBST solutions of primary antibody for two days at room temperature under gentle agitation. For VGLUT1 immunolabeling, either of two different rabbit polyclonal antisera were used, one produced by Bellocchio et al. (1998;  diluted 1:4000) or one commercially obtained (Synaptic Systems; diluted 1:2000-4000).
Similarly, for VGLUT2 immunolabeling, either the antiserum produced by Fremeau et al. (2001; diluted 1:20,000-40,000) or the VGLUT2 antiserum obtained from Synaptic Systems (diluted 1:2000) was used. The concentrations of antibodies were chosen to produce similar staining intensities in the areas most strongly immunoreactive for VGLUT1 and VGLUT2, respectively. To reduce background staining, all primary antibody solutions were preabsorbed with fixed rat liver sections overnight prior to use.
Following the incubation in primary antibody, the sections were rinsed 6 x 10 min in PBS and then incubated in biotinylated swine anti-rabbit (1:30; DAKO) in PBST for one hour. The sections were then rinsed in PBS (3 x 10 min) and incubated in Vectastain ABC Elite solution (Vector; 1 drop each of solutions A and B in 5 ml PBST) for three hours. After further rinses in PBS (3 x 10 min), the sections were processed with the chromogen Vector SG (Vector) to visualize the distribution of bound immuno-complexes. The sections were then rinsed, mounted on slides with a chrome alum gelatin solution and air-dried overnight. Following dehydration in graded ethanols, the sections were cleared in xylene overnight and then coverslipped with DPX (BDH). The sections were examined in a light microscope and photographed with a Polaroid DMC 1 digital microscope camera. Photomicrographs were obtained with a X100 oil-immersion lens (Fig. 1) , a X10 lens (Fig. 3) , or a X40 lens , and mounted and moderately processed in Photoshop (levels, contrast/brightness) to enhance the visibility of labeled profiles.
In six different areas of spinal gray matter (laminae I-II, laminae III-IV, laminae V-VI, lamina VII, lamina VIII and lamina IX) the long diameter of 100 labeled varicosities was measured in each area in two sections from L4 labeled for VGLUT1 or VGLUT2, respectively. Measurements were made using functions in Photoshop on digital photomicrographs obtained with a X100 oil-immersion lens and enlarged to X10,000 on the computer screen. The medium-sized VGLUT1 immunolabeled varicosities in the inner part of lamina II, spatially closely associated with the population of similar varicosities in laminae III-IV, were not included in the analysis of VGLUT1 immunolabeled varicosities in laminae I-II.
Immunofluorescent labeling of the spinocervical tract
To examine if terminals of the spinocervical tract contain VGLUT1 and/or VGLUT2, three Sprague-Dawley rats were anesthetized with sodium pentobarbital (60-70 mg/kg b.w., i.p.) and either the cervical (2 rats) or the lumbar (1 rat) spinal enlargement was uncovered by laminectomies. Using a glass micropipette connected to a Hamilton syringe, choleragenoid (CTb, 1%; List Biological Laboratories) was injected unilaterally into the dorsal horn (five injections of 0.1 µl each, each spaced about 1mm in the rostrocaudal axis). The wound was sutured and the rats allowed to survive for three (cervical injections) or eight (lumbar injections) days. The rats were then deeply anesthetized and fixed by transcardial perfusion as described above. The spinal cord segments containing the injections sites and the C1-3 segments containing the lateral cervical nucleus were harvested and placed in PBS with 30% sucrose overnight.
Parasagittal sections through the injection sites were obtained at 40 µm using a freezing The sections were examined in a Zeiss LSM 510 confocal laser scanning microscope, first using conventional epifluorescence microscopy with a X5 lens to identify areas in the lateral cervical nucleus containing CTb labeled varicosities, and then with confocal microscopy using a X100 oil-immersion lens. To minimize cross talk between the green (500-550 nm) and red (≥560 nm) channels, images were acquired in sequence, rather than simultaneously, so that the detector for 500-550 nm was deactivated while the 543 nm argon laser was on and vice versa.
Several z stacks, of varying depth, were sampled and used in the analysis of double labeling. In some sections, single 1-µm-thick optical slices in one or two 92 X 92 µm large fields in the lateral cervical nucleus, were also sampled. Care was taken to completely separate the selected fields to avoid sampling of individual varicosities twice.
The z stacks were displayed on the computer screen, with the red and green channels side by side, together with a merged red/green image. Varicosities labeled for CTb were identified in the green channel and the corresponding locations in the red and merged channels were inspected in order to determine whether the varicosity were immunolabeled also for VGLUT1 or VGLUT2. In cases where double labeling was uncertain, varicosities were followed through the individual optical slices of the z stack to determine if the VGLUT staining located within the CTb-labeled varicosity or not. Single optical slices were separated into red and green channels, and these were analyzed using the Cell Counter plugin in NIH ImageJ v.
1.34e.
Double immunofluorescence labeling for VGLUT1 and VGLUT2
Wistar rats were deeply anesthetized and fixed by transcardial perfusion by means of a peristaltic pump at a flow rate of about 25 ml/min and per 100 g. A brief flush of 4% dextran (w/v) in 0.1 M sodium phosphate buffer pH 7.4 (NaPi) was followed by 4 % formaldehyde Double immunofluorescence labeling of VGLUT1 and VGLUT2 was made either by simultaneous incubation in antisera from different species or by sequential incubations in antisera from the same species. In the first protocol, sections were incubated overnight at room temperature in a mixture of guinea pig VGLUT1 antibody (Chemicon; 1:5000) and rabbit VGLUT2 antibody (Fremeau et al., 2001 ; 1:1000) in diluent solution, consisting of PBS with 3% (v/v) NGS, 1% (w/v) BSA, 0.5% (w/v) Triton X-100, and 0.05% (w/v) NaN 3 .
After 3 x 5 minutes rinsing in diluent solution, sections were incubated for one hour in a mixture of secondary antibodies (goat anti-guinea pig coupled to Cy3, 1:500; goat anti-rabbit coupled to Cy2, 1:1000; Molecular Probes Inc., Eugene, Oregon, USA) in diluent solution.
The sections were then rinsed in PBS and mounted with Fluoromount G (Southern Biotechnology Associates Inc., Birmingham, Alabama, USA).
A protocol for double labeling using primary antibodies from the same host species was developed from previous reports (Wessel and McClay, 1986; Franzusoff et al., 1991; Lewis Carl et al., 1993) . The solution used for dilution of antisera and rinsing was the same as above unless noted. Sections were incubated overnight at room temperature in rabbit VGLUT1
antibody (Bellocchio et al., 1998; 1:1000) . Following 3 x 5 minutes of rinsing, the sections were incubated in goat anti-rabbit coupled to Cy2 (1:500; Molecular Probes). The sections were then rinsed (3 x 5 minutes) and incubated for 1 hour with rabbit preimmune IgG (12 mg/ml; serum purified from a protein A column as descried in Boulland et al., 2002) to block secondary antibody free arms. Following another rinse (3 x 5 minutes), the sections were incubated for one hour with goat anti-rabbit monovalent Fab (Jackson ImmunoResearch Laboratories Inc., West Groove, PA, USA) at 70 mg/ml to block rabbit Ig epitopes. The sections were then rinsed 3 x 10 min in PBS and fixed for 30 min with 4% formaldehyde dissolved in 0.1 M NaPi. After rinsing 3 x 10 min in PBS, sections were re-blocked as described above and incubated overnight in rabbit VGLUT2 antibody (Fremeau et al., 2001;  1:1000). The sections were then rinsed 3 x 5 min and incubated in goat anti-rabbit coupled to Cy3 (1:500; Molecular Probes). Following rinses in PBS the sections were mounted with Fluoromount G.
Stained sections were examined in a Zeiss confocal unit Pascal 5 LSM mounted on a Zeiss Axioplan 2 microscope. z stack scans were performed using a X63 oil immersion lens.
Pinhole, adjusted around 1 area unit, was optimized for each laser wavelength (488 nm and 568 nm) in order to get the same optical slice for each wavelength. There was no gap in between each picture scanned. The same settings were kept for each z stack scans. Seven z stack scans were performed in lamina IX and seven others were acquired from lamina III-IV.
Double stained terminals were determined in three dimensions to ensure that the yellow staining observed was not due to a close overlap between 2 terminals stained with different dyes. Double stained terminals were counted for each z stack scans. Because the distance scanned in the z varied for each z stack scans, the number of double stained terminals was related to the volume (i.e., optical slices of identical volume; Table 4 ) of tissue scanned.
RESULTS
In the descriptions below, the delineations of spinal cord laminae follows those described by Molander et al. (1984 Molander et al. ( , 1989 . Laminar boundaries were inferred by direct comparison of the labeled sections with the published drawings and micrographs in the cited papers. The delineation between lamina II and III was aided by examination of the sections with dark field optics.
Light microscopic analysis at high magnification revealed that VGLUT1 immunolabeled varicosities in the spinal cord varied largely in size ( Fig. 1 A, C, E; Table 2 ). In contrast, VGLUT2 immunolabeled varicosities displayed a relatively uniform small size throughout the spinal gray matter (Fig. 1 B, D, F; Table 3 ). Measurements of VGLUT1 varicosities in the different laminae indicated the presence of at least two different populations, one of small (≈1-2 µm) and another of medium-sized (≈2-4 µm) to large (≈4-8 µm) varicosities (Fig. 2 ).
Nerve fibers connecting labeled varicosities were also discernable in most regions of the spinal gray matter in the VGLUT1 immunolabeled sections. In some cases, a single VGLUT1
immunolabeled fiber harbored up to ten varicosities. Although a fiber harboring mainly medium-sized to large varicosities occasionally also displayed a relatively small varicosity, and vice versa, most varicosities on a single fiber were of the same size range.
Distribution of VGLUT1 immunolabeling
VGLUT1 immunolabeled varicosities were present in almost all parts of the spinal gray matter, although in different densities and with different appearance (Fig. 3 A 1 Small VGLUT1 immunolabeled varicosities were present in most areas of the spinal gray matter. In the superficial dorsal horn, small VGLUT1 varicosities were present at the highest density in lamina I and in the outer third of lamina II, whereas usually only very sparse VGLUT1 immunolabeling was present in the central third of lamina II (Figs. 1 A, 3 A 1 , B 1 , C 1 , D 1 ). However, in segments C6 and L4 small VGLUT1 varicosities were scattered at about equal density throughout the dorsoventral extent of the medial half of laminae I-II, whereas the lateral half displayed a distribution pattern similar to that of the whole mediolateral extent of laminae I-II at C2 and T8 (Fig. 4 A 1 ) . Small VGLUT1 varicosities were also present in lamina III-VI (Fig. 2) , although their density was difficult to appreciate due to the high density of strongly stained medium-sized to large varicosities. A sparse network of thin fibers with small VGLUT1 varicosities was evident throughout most parts of laminae VII and VIII VGLUT1 immunolabeled varicosities were also present in certain special spinal cord nuclei at different levels. In segment C2 (Fig. 3 A 1 ) , a high density of mostly medium-sized to large varicosities was evident in the central cervical nucleus (Fig. 6 A 1 ). The internal basilar nucleus contained a high density of both small and large VGLUT1 varicosities ( Fig. 6 B 1 ).
Dense VGLUT1 immunolabeling was also noted around scattered neurons in the gracile fasciculus in segments C1 and C2 (Fig. 3 A 1 ) . In the lateral spinal nucleus, located in the white matter ventral to the lateral part of the dorsal horn throughout the spinal cord ( Fig. 3 A 1 , B 1 , C 1 , D 1 ), a relatively low density of small VGLUT1 immunolabeled varicosities were present ( Fig. 6 C 1 ). However, no or only very sparse VGLUT1 immunolabeling was seen in the adjacent lateral cervical nucleus in segments C1-C3 (Figs. 3 A 1 , 6 C 1 ) . In segments T8 and T9, the intermediolateral nucleus ( Fig. 3 C 1 ) was not clearly defined in all sections. However, in many of the sections a small region with a location corresponding to that of the intermediolateral nucleus was virtually devoid of VGLUT1 immunolabeling ( Fig. 7 A 1 ; cf. Stornetta et al., 2002; Nakamura et al., 2005) . Dense VGLUT1 immunolabeling, composed of mainly medium-sized to large varicosities, was present in the column of Clarke ( Fig. 7 B 1 ; cf. Alvarez et al., 2004) . In segments C6 and L4, a cluster of medium-sized to large VGLUT1
immunolabeled varicosities was in many sections evident in the medial-most part of lamina VII at a location corresponding to that of the intermediomedial nucleus ( Fig. 3 B 1 , D 1 ) . A similar pattern of labeling may also be present in segments C2 and T8, although it was often not clearly separable from the dense labeling in the central cervical nucleus and in the column of Clarke, respectively.
In the white matter, the most conspicuous VGLUT1 immunolabeling was that of thin fibers in the pyramidal tract in the ventral part of the dorsal columns (Figs. 3 A 1 , B 1 , C 1 , D 1 , 6
B 1 , 7 B 1 ). Also large axons in the rest of the dorsal column, especially in the gracile fasciculus at rostral levels ( Fig. 3 A 1 ) , had a faint labeling that exceeded that seen in most axons in the lateral and ventral funiculi. Sparse small VGLUT1 immunolabeled varicosities were also present in bundles extending from the spinal gray matter into the lateral and ventral funiculi.
Distribution of VGLUT2 immunolabeling and comparison with VGLUT1
VGLUT2 immunolabeling was present in all areas of the spinal gray matter ( Fig. 1 A 2 Tables 2, 3) , although some larger, usually faintly labeled, varicosities were evident in some areas, e.g. laminae III-IV, lamina IX and the column of Clarke. Only small differences in the average size of VGLUT2 immunolabeled varicosities were noted between different areas of the spinal gray matter (Table 3) .
Generally, areas with sparse VGLUT1 immunolabeled large varicosities were the areas that contained the highest densities of VGLUT2 immunolabeling ( Fig. 3 A 2 , B 2 , C 2 , D 2 ). In the dorsal horn, relatively sparse VGLUT2 immunolabeling was present in laminae III-IV and in the central/medial parts of laminae V-VI, whereas high densities of VGLUT2 labeling were evident in the superficial dorsal horn, especially in lamina I and the outer part of lamina II (Figs. 1 B, 4 A 2 ), and in the lateral parts of laminae V-VI (Fig. 4 B 2 ). In the intermediate zone and ventral horn, displaying overall high VGLUT2 labeling densities (Figs. 1 D, F, 3 A 2 , B 2 , C 2 , D 2 ), slightly higher labeling densities were seen in lamina VIII as compared to laminae VII and IX ( Fig. 5 A 2 , B 2 ). These differences in VGLUT2 labeling density between laminae VII-IX were more apparent in the spinal enlargements ( Fig. 3 B 2 , D 2 ). In segments C2 ( Fig. 3 A 2 ) and T8 ( Fig. 3 C 2 ) VGLUT2 immunolabeling density in the ventral spinal gray matter appeared homogeneous except for a slightly lower labeling density in lamina IX.
In the central cervical nucleus, the internal basilar nucleus and the column of Clarke, all containing high densities of VGLUT1 immunolabeling, only sparse VGLUT2 immunolabeling were present (Figs. 6 A, B, 7 B) . Both the lateral spinal and lateral cervical nuclei contained relatively high densities of VGLUT2 immunolabeled varicosities ( Fig. 6 C 2 ).
In segments T8 and T9, VGLUT2 immunolabeling density in the intermediolateral nucleus was not appreciably different from that in the adjacent areas of laminae V and VII (Figs. 3 C 2 , 7 A 2 ). Lamina X contained a relatively high density of mostly small VGLUT2 immunolabeled varicosities (Figs. 3 A 2 , B 2 , C 2 , D 2 , 7 B 2 ).
Anterograde CTb labeling of spinocervical tract varicosities in the lateral cervical nucleus and simultaneous immunolabeling for VGLUT1 or VGLUT2 (Fig. 8) , demonstrated that virtually all spinocervical tract varicosities (97.4-98.1%) were immunoreactive for VGLUT2
(n = 156-165 in each of three rats). In contrast, only 6 out of 480 examined spinocervical tract varicosities (1.3%) were judged to contain immunoreactivity for VGLUT1. However, immunofluorescence for VGLUT1 in the few immunopositive varicosities was only slightly above background and similar to or fainter than that evident in the most sparsely labeled VGLUT2-postive spinocervical tract varicosities.
Except for faint background staining, no labeling similar to that of the pyramidal tract in VGLUT1 immunolabeled sections was evident in the spinal white matter of VGLUT2 immunolabeled sections. However, the bundles extending from the spinal gray matter into the lateral and ventral funiculi, which contained only sparse small VGLUT1 immunolabeled varicosities, harbored a relatively high density of small VGLUT2 immunolabeled varicosities (Figs. 3, 5 B) . The presence of such varicosities often extended almost all the way to the spinal cord surface.
Co-localization of VGLUT1 and VGLUT2
Examination of sections immunofluorescence-stained for both VGLUT1 and VGLUT2 demonstrated a distribution pattern of the transporters essentially identical to that evident in immunoperoxidase stained sections ( Fig. 9 ; cf. Fig. 3A) . The double staining performed with antibodies raised in the same host species (see Material and Methods) gave the same results as the double staining using antibodies raised in different host species. Control sections incubated without primary antibodies showed a faint, diffuse and homogeneous background (not shown).
Analysis of double stained sections with confocal microscopy demonstrated that the majority of immunolabeled varicosities in the spinal cord were labeled for either VGLUT1 or VGLUT2. However, in both laminae III-IV and lamina IX, a proportion of varicosities was labeled for both transporters (Fig. 9C) . The density of double-labeled varicosities was significantly higher in laminae III-IV than in lamina IX (Table 4) . Reconstruction of double labeled terminals at high magnification by serial confocal scans in the z axis, without gap in between the scans, demonstrated colocalization of the VGLUT1 and VGLUT2 in the xy, xz, yz axes (Fig. 9C, inset) , excluding possible false colocalization due to close apposition of structures differently stained. 
DISCUSSION
Origin of immunolabeled terminals
VGLUT1. There is now abundant evidence that VGLUT1 is present in large diameter low threshold skin and muscle primary afferent terminals in the spinal cord, corroborating extensive electrophysiological/pharmacological and glutamate immunogold labeling data supporting a transmitter role of glutamate in such terminals (e.g. Salt and Hill, 1983; Jahr and Yoshioka, 1986; Schouenborg and Sjölund, 1986; Gerber and Randic, 1989; Walmsley and Nicol, 1991; Maxwell et al., 1990a; Broman et al., 1993; Maxwell et al., 1993; Broman and Ådahl, 1994; Valtschanoff et al., 1994; Örnung et al., 1995; Larsson et al., 2001; Ragnarson et al., 2003) . Dorsal rhizotomy results in significant depletion of large VGLUT1 immunolabeled varicosities in the ventral horn and deep dorsal horn (Li et al., 2003; Oliveira et al., 2003; Alvarez et al., 2004; Wu et al., 2004) , and essentially all primary afferent terminals in these VGLUT1 and VGLUT2 co-localize in a proportion of varicosities in laminae III-IV and lamina IX, further support the notion that some primary afferent terminals in both the deep dorsal horn and the ventral horn express VGLUT2 in addition to VGLUT1. In the rodent brain, an extensive expression of VGLUT2 is evident already at birth (Boulland et al., 2004; Fremeau et al., 2004a) . In contrast, expression of VGLUT1 is sparse at birth and then increases progressively during postnatal development. In many regions, VGLUT2 is downregulated in parallel with an increase in VGLUT1 expression. It is thus tempting to speculate that the expression pattern in large caliber primary afferents in adult rats, i.e. sparse presence of VGLUT2 in fibers primarily expressing VGLUT1, reflects developmental changes. A likely scenario in light of the above observations would be an initial high VGLUT2 expression and absent or low VGLUT1 expression in these fibers that, during the course of development, is replaced by a high VGLUT1 expression and sparse expression of VGLUT2, similar to the change noted in cerebellar parallel fibers (Miyazaki et al., 2003) . Such a scenario would be concordant with findings in VGLUT1 knockout mice, which display no gross phenotype abnormalities at birth but gradually develops neurological defects from 2-3 weeks after birth (Fremeau et al., 2004a) . However, whether developmental changes in VGLUT expression occur also in the spinal cord remains to be demonstrated.
Another important source for VGLUT1 immunolabeled varicosities in the spinal cord is the pyramidal tract. We detected clear VGLUT1 immunolabeling, but no VGLUT2
immunolabeling, in pyramidal tract axons in the ventral part of the dorsal column (see also Alvarez et al., 2004) . Further, the distribution pattern of small VGLUT1 immunolabeled varicosities in the spinal cord, i.e. their presence in most laminae though sparse in lamina IX in comparison to laminae VII-VIII, and in segments C6 and L4 more extensive throughout the medial half than the lateral half of lamina I-II, closely resembles the distribution of anterogradely labeled corticospinal tract axon terminals in rats and cats (Cheema et al., 1984; Casale et al., 1988; Liang et al., 1991; Valtschanoff et al., 1993) . VGLUT1 mRNA is also highly expressed in the deep layers of the cerebral cortex where corticospinal tract neurons are located (Ni et al., 1994; Fremeau et al., 2001; Herzog et al., 2001 ). Thus, it appears likely that at least a sizable proportion of small VGLUT1 varicosities originate in the cerebral cortex.
However, only a proportion of the small VGLUT1 varicosities in laminae I-II has a distribution equivalent to that observed for corticospinal terminations. The corticospinal tract terminations in laminae I-II locate primarily in the medial part of the dorsal horn in the spinal enlargements, corresponding somatotopically to the distal parts of the limbs (Casale et al., 1988) . Thus, the small VGLUT1 varicosities, present at low to moderate density throughout the mediolateral and rostrocaudal extent of laminae I and IIo, presumably mainly have Alternatively, a subpopulation of primary afferents in laminae I-II not identified by the labeling techniques or criteria used in previous studies principally express VGLUT1.
The detection of VGLUT1 immunolabeling in pyramidal tract axons, and to some extent also in axons of the dorsal column, suggests that some axons may harbor significant amounts of VGLUT1-containing vesicles presumably under transport towards the axon terminals. In contrast, we found no clear VGLUT2 immunolabeling of axons in the spinal white matter, indicating absence or low levels of this antigen. Although this possibly could be explained by different detection sensitivities (i.e., a higher sensitivity of the VGLUT1 antisera in detecting low levels of antigen), it may also reflect a true difference in the levels of these antigens in axons, possibly related to differences in membrane trafficking between VGLUT1 and VGLUT2 (Fremeau et al., 2004a ). but relatively low levels of VGLUT2 in most presumed C-fiber primary afferent terminals in lamina II. Thus, it appears that most primary afferent terminals in the superficial dorsal horn contain VGLUT2, although at levels lower than those in terminals originating from dorsal horn local circuit neurons (Todd et al., 2003) . This presumably explains why their disappearance is usually undetected following dorsal rhizotomy. Primary afferent terminals in lamina II contain high levels of glutamate (DeBiasi and Rustioni, 1988; Maxwell et al., 1990b; Broman et al., 1993; Broman and Ådahl, 1994; Valtschanoff et al., 1994; Larsson et al., 2001) and there is abundant physiological/pharmacological evidence that support glutamate as a fast primary afferent neurotransmitter in such terminals (e.g. Weinberg, 1989, Aanonsen et al., 1990; Broman et al., 2000) . Whether the relatively low VGLUT2-levels in primary afferent C-fiber terminals are sufficient to sustain the release of glutamate from these terminals or if other mechanisms are involved remains to be elucidated.
VGLUT2 mRNA is expressed in neurons scattered throughout large parts of the spinal gray matter, including sparsely labeled neurons in the superficial dorsal horn (Kullander et al., 2003; Oliveira et al., 2003; Landry et al., 2004; Herzog et al., 2004) . Consequently, Todd et al. (2003) detected VGLUT2 immunolabeling in most of the superficial dorsal horn terminals that originate from certain populations of excitatory local circuit neurons. Some of the VGLUT2 expressing neurons in the ventral horn are suggested to be an excitatory component in the spinal central pattern generator (Kullander et al., 2003) , and axonal varicosities from a proportion of commissural interneurons in the ventral horn are immunolabeled for VGLUT2 (Bannatyne et al., 2003) . As a substantial population of spinal cord neurons express VGLUT2
mRNA, it appears likely that many of the VGLUT2 immunolabeled varicosities in laminae express VGLUT2 mRNA and contain VGLUT2 in their terminals (Stornetta et al., 2003; Yokota et al., 2003) , as do terminals in the phrenic nucleus originating from neurons in the Kölliker-Fuse nucleus (Yokota et al., 2003) . Further, neurons in the rostral ventrolateral medulla projecting to the spinal cord express VGLUT2 mRNA (Stornetta et al., 2002) .
Recently, Landry et al. (2004) and Herzog et al. (2004) demonstrated expression of VGLUT1 and VGLUT2 mRNA in motoneurons. Herzog et al. (2004) also demonstrated that some motoneuron axon collaterals were VGLUT2 immunopositive and some of these contacted calbindin immunolabeled neurons (presumably Renshaw cells). Thus, some VGLUT2 immunolabeled varicosities in the ventral horn may originate from motoneurons.
The lateral cervical nucleus was found to be virtually devoid of VGLUT1
immunolabeling but to contain dense labeling for VGLUT2. Neurons in the lateral cervical nucleus relay sensory information from spinocervical tract neurons in the ipsilateral dorsal horn to among others the contralateral ventral posterior lateral nucleus of the thalamus (Giesler et al., 1988; Zhang et al., 2002) . Previous studies in cats have demonstrated that terminals of the spinocervical tract contain high levels of glutamate associated with synaptic vesicles but low levels of glutamine (Broman et al., 1990; Broman, 1994, 1995) , making strong arguments for glutamate as a spinocervical tract neurotransmitter in cats. Our present demonstration that virtually all spinocervical tract terminations in rats are immunoreactive for VGLUT2 strongly support glutamate as a spinocervical tract neurotransmitter also in rats, and demonstrate that vesicular accumulation of glutamate in spinocervical tract terminals is sustained primarily if not exclusively by VGLUT2.
Functional considerations
Based on the presence of either VGLUT1 or VGLUT2 in select nerve terminal populations in primarily the hippocampus and the cerebellum (e.g. cerebellar climbing fibers, expressing VGLUT2, and parallel fibers, expressing VGLUT1) a role in determining release probability for the VGLUTs has been proposed (Fremeau et al., 2001; Varoqui et al., 2002) . Thus, VGLUT1 is expressed in terminals with low probability of release and activity-dependent potentiation, whereas VGLUT2 is expressed in terminals displaying high probability of release and high-fidelity neurotransmission. The explanation for such a difference is not clear, but may be related to differences in the cytoplasmic C-termini of VGLUT1 and VGLUT2, resulting in different protein-protein interactions of the transporters that could affect the mode and rate of synaptic vesicle recycling (Fremeau et al., 2004a,b) . For example, synaptic vesicles in cerebellar climbing fiber and parallel fiber terminals associate with different G protein subunits (Pahner et al., 2003) .
Most glutamatergic fiber systems in the spinal cord should display high probability of release and high-fidelity neurotransmission due to their use of VGLUT2 as vesicular transporter. This should be the case for most intrinsic glutamatergic neurons, glutamatergic projections from the brainstem and also the spinocervical tract (and presumably also other ascending spinal sensory pathways as judged from the distribution of neurons expressing mRNA for VGLUT1 or VGLUT2; Kullander et al., 2003; Oliveira et al., 2003) . The major VGLUT1 immunoreactive fiber systems in the spinal cord, i.e. the corticospinal tract and the large caliber skin and muscle primary afferents, should in contrast form synapses with lower release probability. To our knowledge, detailed studies of release probability in primary afferent synapses are sparse. Ia afferent synapses with motoneurons and dorsal spinocerebellar tract neurons have been examined (Redman and Walmsley, 1983; Walmsley et al., 1988; Clamann et al., 1989) , and most such synapses appear to have low probabilities of release, thus supporting a correlation between use of VGLUT1 and low release probability.
However, a significant proportion of such synapses do display high release probability.
Furthermore, the interpretation of data is complicated by the co-expression of VGLUT1 and VGLUT2 in mechanoreceptor afferent terminals (Todd et al., 2003; Oliveira et al., 2003; Alvarez et al., 2004 ; present study).
Another potentially important issue, so far receiving little attention, is whether the levels of VGLUTs in primary afferent fibers are subject to regulation in a manner similar to the positive or negative effects on peptide expression in dorsal root ganglion neurons evident after peripheral nerve injury or peripheral inflammation (Willis and Coggeshall, 2004) . immunolabeling in corresponding areas in the dorsal horn of segment L4. Medial is to the right and dorsal is upward. The photomicrographs in B are from the center of laminae V-VI and include a small part of lamina VII (cf. Fig. 3 D) . I, lamina I; II, lamina II; III, lamina III;
IV, lamina IV; V, lamina V; VI, lamina VI; VII, laminae VII. Calibration bar in B 2 (valid for all photomicrographs), 100 µm. part of the ventral funiculus at the extreme right (cf. Fig. 3 B) . In B, medial is to the right and dorsal is upward. VII, lamina VII; VIII, lamina VIII; IX, lamina IX. Calibration bar in A 1
(valid for all photomicrographs), 100 µm. 1. I-II 1.4±0.4 -*** *** *** *** 2.5±1.1 *** -*** *** 5. VIII 1.6±0.4 *** *** *** -*** 6. IX 3.2±1.4 *** *** *** *** *** -
